⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

Jefferies downgrades Masimo to Hold as 'good news baked in'

Published 01/30/2024, 10:36 AM
Updated 01/30/2024, 10:45 AM
© Reuters.  Jefferies downgrades Masimo (MASI) to Hold as ‘good news baked in’
MASI
-

Jefferies has downgraded global medical technology firm Masimo (NASDAQ:MASI) to ‘Hold’ from ‘Buy.’ At the same time, the analysts set a new higher price target of $121 for the stock. The change is based on current valuations and the view that the positive outlook for the company is already baked in.

“Overall, we think the worst is behind MASI, following a challenging '23 that included multiple downward revisions,” the analysts wrote in a note to clients Monday.

The downgrade comes even as Jefferies observes that Masimo’s trends and outlook have improved, especially in the HC business. Other positives include the company’s recent win vs. AAPL on its ITC challenge, and some relief post a '24 guide that “alleviated concerns about costs returning and sapping EPS growth.”

“That said, we now see a lot of good news baked in and are moving to the sidelines based on valuation,” they wrote.

With shares up over 65% since October lows and trading at ~42x forward EPS, (~37x using new Non-GAAP), Jefferies no longer views MASI as cheap for growth, noting it traded through the previous price target.

“[F]undamental upside from here could be limited,” they wrote.

Following the downgrade, Masimo stock is trading down 1.95% Tuesday morning at $127.72.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.